🇺🇸 FDA

Company profile · Sponsor

Tango

Tango Therapeutics

TNGX · NYSE pharma BOSTON, MA, USA
Pipeline
7
Drugs
0
Patents
8

Quick answer

Tango (TNGX) is a pharma company. headquartered in BOSTON, MA, USA. listed on NYSE. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker TNGX
Exchange NYSE
Company type pharma
Headquarters BOSTON, MA, USA
SEC CIK 0001819133

Pipeline (7)

Search pipeline →

  1. S095035

    Tango

    MTAP-deleted Solid Tumors

    phase 2 small molecule active

    1 trial

  2. TNG260

    Tango

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. TNG348

    Tango

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  4. TNG456

    Tango

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  5. TNG462

    Tango

    Locally Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  6. TNG908

    Tango

    Locally Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  7. TNG908, TNG908, TNG908, TNG908, MIDAZOLAM

    Tango

    "Ph1: •Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors •MTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM) Ph2: A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC A2:LA or met.MTAP-del. mesothelioma A3:LA or met.MTAP-del. sarcoma A4:LA or met.MTAP-del. pancreatic ductal adenocarcinoma or adenosquamous carcinoma w/predominantly adenocarcinoma histology A5:Other LA or met.MTAP-del. solid tumors A6:MTAP-del. R/R GBM"

    phase 2 small molecule active

    1 trial

Patents (8)

Search patents →

  1. US 12403137

    Compounds and methods of use

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12304907

    Compounds and methods of use

    Expires Mon May 15 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12264154

    Compounds and methods of use

    Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12043607

    HDAC inhibitors and therapeutic use thereof

    Expires Mon Jul 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11999727

    Compounds and methods of use

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11986471

    Compounds and methods of use

    Expires Mon May 16 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11492350

    Compounds and methods of use

    Expires Mon Nov 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11077101

    Compounds and methods of use

    Expires Mon Jul 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Tango?

Tango (TNGX) is a pharma company. headquartered in BOSTON, MA, USA. listed on NYSE. NovaPharmaNews links 7 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Tango sponsor?

We track 7 ClinicalTrials.gov-linked programs for Tango, including S095035 and 6 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Tango company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.